Design and Synthesis of Mono-, Di-, Tri- and Tetraindoles Derivatives as Novel Histone Deacetylase Inhibitors

以作者查詢圖書館館藏

、以作者查詢臺灣博碩士

、以作者查詢全國書目

、勘誤回報

、線上人數：1

、訪客IP：3.129.63.114

姓名

吳佳欣(Chia-Hsin Wu) 查詢紙本館藏

畢業系所

化學學系

論文名稱

(Design and Synthesis of Mono-, Di-, Tri- and Tetraindoles Derivatives as Novel Histone Deacetylase Inhibitors)

★ Synthesis and biological evaluation of pyrazole derivatives as antitumor agents

檔案

[Endnote RIS 格式]

[Bibtex 格式]

[相關文章]

[文章引用]

[完整記錄]

[館藏目錄]

[檢視]

[下載]

本電子論文使用權限為同意立即開放。
已達開放權限電子全文僅授權使用者為學術研究之目的，進行個人非營利性質之檢索、閱讀、列印。
請遵守中華民國著作權法之相關規定，切勿任意重製、散佈、改作、轉貼、播送，以免觸法。

摘要(中)

在這次的研究中，我們設計合成了一系列的單，雙，三，和四吲哚的衍生物(CHW01-03, CHW05, CHW04 and AMB09-10)，它們具有類似Vorinostat （suberanilohydroxamic acid）的側鏈，為FDA批准的HDAC抑制劑。在本篇論文中，我們設計和合成了一系列化合物，以測試其對組蛋白脫乙酰基酶（HDAC）的抑制和對TNBC癌細胞系MDA-MB-231的抑制生長的功能。在此系列化合物中，CHW03對MDA-MB-231細胞株具有最佳的抗增值能力，IC50值為1.4 µM。另外，關於組蛋白脫乙酰基酶抑制的進一步研究也正在研究中。

摘要(英)

In this investigation, we discovered a series of mono-, di-, tri-, and tetraindoles derivatives (CHW01-03, CHW05, CHW04 and AMB09-10), possessing different number of indole rings and similar side chain like Vorinostat (SAHA), a HDAC inhibitor approved by FDA. Their inhibition of histone deacetylase (HDAC) and the inhibitory growth against TNBC cancer cell line MDA-MB-231 was evaluated. Among this series of compounds, CHW03 has the best antiproliferative activity against MDA-MB-231 cell line with an IC50 value of 1.4 µM. Further study in histone deacetylase inhibition is in progress.

關鍵字(中)

★ 組織蛋白去乙醯酶抑制劑
★ 四吲哚衍生物
★ 抗三陰性乳癌藥物

關鍵字(英)

★ Histone deacetylase inhibitor
★ Tetraindole derivatives
★ TNBC anticancer agent

論文目次

Table of Contents
摘要 i
Abstract ii
誌謝 iii
Table of Contents iv
List of Figures vii
List of Tables viii
List of Schemes ix
List of Abbreviation x
Ⅰ. Introduction 1
1.1 Background 1
1.2 Introduction of triple negative breast cancer (TNBC) 2
1.2.1 Introduction of breast cancer 2
1.2.2 Introduction of triple negative breast cancer (TNBC) 3
1.2.3 Treatment of triple negative breast cancer (TNBC) 4
1.3 Introduction of tetraindole 8
1.3.1 Bio-inspired invention of tetraindole 8
1.3.2 Literature review of tetraindole 9
1.4 Introduction of Histone Deacetylase Inhibitor (HDACi) 10
1.4.1 Histone deacetylase inhibitor (HDACi) 10
1.4.2 Structure studies of histone deacetylase inhibitor (HDACi) 11
Ⅱ. Results and Discussion 12
2.1 Research Motivation 12
2.2 Retrosynthetic Analysis of Indole–Based HDAC Inhibitors 13
2.3 Synthesis of SAHA–Linker 3 15
2.4 Synthesis of Indole–based HDAC inhibitors 16
2.4.1 Synthetic route of AMB09 16
2.4.2 Synthetic route of AMB10 17
2.4.3 Synthetic route of CHW01 and CHW02 18
2.4.4 Synthetic route of CHW03 19
2.4.5 Synthetic route of CHW04 20
2.4.6 Synthetic route of CHW05 21
2.5 In Vitro Studies of AMB09-10, and CHW01-05 22
2.5.1 Cytotoxicity of AMB09-10 on MDA-MB-231 cell proliferation 22
2.5.2 Cytotoxicity of CHW01-05 on MDA-MB-231 cell proliferation 24
2.6 Preliminary Structure-Activity Relationship Studies 27
Ⅲ. Conclusions 28
Ⅳ. Materials and Methods 29
4.1 General Information 29
4.2 Experimental Method 30
4.2.1 Synthesis of SAHA–linker 3 30
4.2.2 Synthesis of AMB09 31
4.2.3 Synthesis of AMB10 35
4.2.4 Synthesis of CHW01 39
4.2.5 Synthesis of CHW02 41
4.2.6 Synthesis of CHW03 43
4.2.7 Synthesis of CHW04 46
4.2.8 Synthesis of CHW05 50
4.3 Cell Line Used and Cell Culture 52
4.4 MTT Cytotoxicity Analysis 52
Ⅴ. References 53
Ⅵ. Spectra Appendix 58

參考文獻

Ⅴ. References
1. 衛生福利部國民衛生署癌症登記報告https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=10227.
2. 衛生福利部統計處107年主要死因統計結果分析 https://dep.mohw.gov.tw/DOS/lp-4472-113.html.
3. Ganesh N. Sharma; Rahul Dave; Jyotsana Sanadya; Piush Sharma; K. K. Sharma. Various Types and Management of Breast Cancer: An Overview. J. Adv. Pharm. Technol. Res., 2010, 2, 109–126.
4. Atif Ali Hashmi; Saher Aijaz; Saadia Mehmood Khan; Raeesa Mahboob; Muhammad Irfan; Narisa Iftikhar Zafar; Mariam Nisar; Maham Siddiqui; Muhammad Muzzammil Edhi; Naveen Faridi; Amir Khan. Prognostic Parameters of Luminal A and Luminal B Intrinsic Breast Cancer Subtypes of Pakistani Patients. World J. Surg. Oncol., 2018, 16, 1–6.
5. William D. Foulkes; Ian E. Smith; Jorge S. Reis-Filho. Triple-Negative Breast Cancer. N. Engl. J. Med., 2010, 363, 1938–1948.
6. Haixia Chen; Jianming Wu; Zhihong Zhang; Yong Tang; Xiaoxuan Li ; Shuangqing Liu; Shousong Cao; Xianzhu Li. Association between BRCA Status and Triple-Negative Breast Cancer: A Meta-analysis. Front Pharmacol. 2018, 9, 1–6.
7. Chao Wang; Shreya Kar; Xianning Lai; Wanpei Cai; Frank Arfuso; Gautam Sethi; Peter E. Lobie; Boon C. Goh; Lina H.K. Lim; Mikael Hartman; Ching W. Chan; Soo C. Lee; Sing H. Tan; Alan P. Kumar. Triple Negative Breast Cancer in Asia: An Insider’s View. Cancer Treat. Rev., 2018, 62, 29–38.
8. Bruce G. Haffty; Qifeng Yang; Michael Reiss. Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer. J. Clin. Oncol. 2006, 24, 5652–5657.
9. Hanan Ahmed Wahba; Hend Ahmed El-Hadaad. Current Approaches in Treatment of Triple-Negative Breast Cancer. Cancer boil. Med., 2015, 12, 106–116.
10. Jessa Gilda P. Pandy; Joanmarie C. Balolong Garcia; Mel Valerie B. Cruz Ordinario ; Frances Victoria F. Que. Triple Negative Breast Cancer and Platinum-Based Systemic Treatment: A Meta-analysis and Systematic Review. BMC Cancer, 2019, 19, 1–9.
11. Luca Livraghi: Judy E. Garber. PARP Inhibitors in the Management of Breast Cancer: Current Data and Future Prospects. BMC Med., 2015, 13, 1–16.
12. Mark Robson; Seock-Ah Im; Elżbieta Senkus; Binghe Xu; Susan M. Domchek; Norikazu Masuda; Suzette Delaloge; Wei Li; Nadine Tung; Anne Armstrong; Wenting Wu; Carsten Goessl; Sarah Runswick; Pierfranco Conte. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N. Engl. J. Med., 2017, 377, 523–533.
13. Xuan Jiang; Weihua Li; Xiaoying Li; Huimin Bai; Zhenyu Zhang. Current Status and Future Prospects of PARP Inhibitor Clinical Trials in Ovarian Cancer. Cancer Manag. Res. 2019, 11, 4371–4390.
14. Jill J. J. Geenen; Sabine C. Linn; Jos H. Beijnen; Jan H. M. Schellens. PARP Inhibitors in the Treatment of Triple Negative Breast Cancer. Clin. Pharmacokinet. 2018, 57, 427–437.
15. Tanya E. Keenan; Sara M. Tolaney. Role of Immunotherapy in Triple-Negative Breast Cancer. J. Natl. Compr. Canc. Netw. 2020, 18, 479–489.
16. Isaac Kim; Katherine Sanchez; Heather L. McArthur; David Page. Immunotherapy in Triple-Negative Breast Cancer: Present and Future. Curr. Breast Cancer Rep. 2019, 11, 259–271.
17. Preeti Narayan; Sakar Wahby; Jennifer J. Gao. FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1. Clin. Cancer Res. 2020, 26, 2284–2289.
18. Terese Winslow LLC, Medical and Scientific Illustration
19. Akintunde Akinleye; Zoaib Rasool. Immune Checkpoint Inhibitors of PD-L1 as Cancer Therapeutics. J. Hematol. Oncol., 2019, 12, 1–13.
20. Jing-Ru Weng; Chen-Hsun Tsai; Samuel K. Kulp; Ching-Shih Chen. Indole-3-Carbinol as a Chemopreventive and Anti-cancer Agent. Cancer Lett, 2008, 262, 153–163.
21. B. P. Bandgar; K. A. Shaikh. Molecular Iodine-catalyzed Efficient and Highly Rapid Synthesis of Bis(indolyl)methanes under Mild Conditions. Tetrahedron Lett. , 2003, 44, 1959–1961.
22. Morteza Shiri; Mohammad Ali Zolfigol; Hendrik Gerhardus Kruger; Zahra Tanbakouchian. Bis- and Trisindolylmethanes. Chem. Rev., 2010, 110, 2250–2293.
23. Mauro De Santi; Luca Galluzzi; Simone Lucarini; Maria Filomena Paoletti; Alessandra Fraternale; Andrea Duranti; Cinzia De Marco; Mirco Fanelli; Nadia Zaffaroni; Giorgio Brandi; Mauro Magnani. The Indole-3-Carbinol Cyclic Tetrameric Derivative CTet Inhibits Cell Proliferation via Overexpression of p21/CDKN1A in both Estrogen Receptor Positive and Triple-Negative Breast Cancer Cell Lines. Breast Cancer Res., 2011, 13, R33.
24. Wen-Shan Li; Chie-Hong Wang; Shengkai Ko; Tzu Ting Chang; Ya Ching Jen; Ching-Fa Yao; Shivaji V. More; Shu-Chuan Jao. Synthesis and Evaluation of the Cytotoxicities of Tetraindoles: Observation that the 5-Hydroxy Tetraindole (SK228) Induces G2 Arrest and Apoptosis in Human Breast Cancer Cells. J. Med. Chem., 2012, 55, 1583–1592.
25. Chie-Hong Wang; Chia-Ling Chen; Shivaji V. More1; Pei-Wen Hsiao; Wen-Chun Hung3; Wen-Shan Li. The Tetraindole SK228 Reverses the Epithelial-to-Mesenchymal Transition of Breast Cancer Cells by Up-Regulating Members of the miR-200 Family. PLoS ONE, 2014, 9, e101088.
26. Chih-Wei Fu; Yun-Jung Hsieh; Tzu Ting Chang; Chia-Ling Chen; Cheng-Yu Yang; Anne Liao; Pei-Wen Hsiao; Wen-Shan Li. Anticancer Efficacy of Unique Pyridine-based Tetraindoles. Eur. J. Med. Chem., 2015, 104, 165–176.
27. Hajjaj H. M. Abdu-Allah; Shih-Ting Huang; Tzu Ting Chang; Chia-Ling Chen; Han-Chung Wu; Wen-Shan Li. Nature-inspired Design of Tetraindoles: Optimization of the Core Structure and Evaluation of Structure–Activity Relationship. Bioorg. Med. Chem. Lett., 2016, 26, 4497–4503.
28. Hui Yang; Tal Salz; Maria Zajac Kaye; Daiqing Liao; Suming Huang; Yi Qiu. Overexpression of Histone Deacetylases in Cancer Cells is Controlled by Interplay of Transcription Factors and Epigenetic Modulators. FASEB J., 2014, 28, 4265–4279.
29. Somy Yoon; Gwang Hyeon Eom. HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. Chonnam. Med. J., 2016, 52, 1–11.
30. Takeshi Harada; Teru Hideshima; Kenneth C. Anderson. Histone Deacetylase Inhibitors in Multiple Myeloma: from Bench to Bedside. Int. J. Hematol., 2016, 104, 300–309.
31. Katherine Ververis; Alison Hiong; Tom C. Karagiannis; Paul V. Licciardi. Histone Deacetylase Inhibitors (HDACIs): Multitargeted Anticancer Agents. Biol. Targets Ther., 2013, 7, 47–60.
32. Annabelle L. Rodd; Katherine Ververis; Tom C. Karagiannis. Current and Emerging Therapeutics for Cutaneous T-Cell Lymphoma: Histone Deacetylase Inhibitors. Lymphoma, 2012, 290685–290695.
33. Edward Seto; Minoru Yoshida. Erasers of Histone Acetylation: the Histone Deacetylase Enzymes. Cold Spring Harb. Perspect. Biol., 2014, 6, a018713.
34. Paul A Marks; Ronald Breslow. Dimethyl Sulfoxide to Vorinostat: Development of this Histone Deacetylase Inhibitor as an Anticancer Drug. Nat. Biotechnol., 2007, 25, 84–90.
35. Anton V. Bieliauskas; Sujith V. W. Weerasinghe; Ahmed T. Negmeldin; Mary Kay H. Pflum. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid. Arch. Pharm. Chem. Life Sci., 2016, 349, 373–382.
36. Wayne W. Hancock; Tatiana Akimova; Ulf H Beier; Yujie Liu; Liqing Wang. HDAC Inhibitor Therapy in Autoimmunity and Transplantation. Ann. Rheum. Dis., 2012, 71, 46–54.
37. Yujia Dai; Yan Guo; Jun Guo; Lori J. Pease; Junling Li; Patrick A. Marcotte; Keith B. Glaser; Paul Tapang; Daniel H. Albert; Paul L. Richardson; Steven K. Davidsen; Michael R. Michaelides. Indole Amide Hydroxamic Acids as Potent Inhibitors of Histone Deacetylases. Bioorg. Med. Chem. Lett., 2003, 13, 1897–1901.
38. Zhao-Ying Yang; Tian Tian; Ya-Fei Du; Shi-Yi Li; Cen-Cen Chu; Lu-Ying Chen;
Dan Li; Jia-Yi Liub; Bin Wang. Direct intramolecular amination of tryptophan esters to prepare pyrrolo[2,3-b]indoles. Chem. Commun., 2017, 53, 8050–8053
39. William K. Hagmann. The Many Roles for Fluorine in Medicinal Chemistry. J. Med. Chem., 2008, 51, 4359–4369.
40. CHROMA THERAPEUTICS LTD WO 2006/117549, 2006, A1

指導教授

李文山侯敦仁(Wen-Shan Li Duen-Ren Hou)

審核日期

2020-7-28

推文